Viridian Therapeutics (NASDAQ:VRDN) reported its Q1 earnings results on Tuesday, May 9, 2023 at 04:01 PM.
Here’s what investors need to know about the announcement.
Earnings
Viridian Therapeutics missed estimated earnings by 57.84%, reporting an EPS of $-1.61 versus an estimate of $-1.02.
Revenue was down $118 thousand from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.4 which was followed by a 0.54% drop in the share price the next day.
Here’s a look at Viridian Therapeutics’s past performance:
| Quarter | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|
| EPS Estimate | -0.73 | -0.95 | -0.90 | -1.08 |
| EPS Actual | -1.13 | -0.86 | -1.06 | -0.98 |
| Revenue Estimate | 510K | 260K | 230K | 300K |
| Revenue Actual | 105K | 1.20M | 256K | 216K |
To track all earnings releases for Viridian Therapeutics visit their earnings calendar here.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
